Sarepta to initiate pivotal Part B of MOMENTUM study for SRP-5051 in DMD patients

Sarepta Therapeutics, Inc.

Positive FDA interactions enable early start of Part B of MOMENTUM study for SRP-5051.
Part B expected to serve as pivotal study seeking accelerated approval for exon 51 skipping DMD patients.
Study will enroll 20-40 patients, ages 7-21, both ambulatory and non-ambulatory.
Company anticipates initiating Part B in Q4 2021; protocol submission next week.
SRP-5051 is a next-generation PPMO therapy; prior Part A data suggested efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.